Liquid biopsies, are we ready for prime time?
作者信息
Normanno Nicola, Apostolidis Kathi, Stewart Mark
机构信息
Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
European Cancer Patient Coalition, Bruxelles, Belgium.
出版信息
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006302.
Abstract
摘要
相似文献
1
Liquid biopsies, are we ready for prime time?液体活检，我们准备好迎接黄金时代了吗？
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006302.
2
Are Liquid Biopsies Ready for Prime Time of Clinical Applications?液体活检是否已准备好迎接临床应用的黄金时代？
J Thorac Oncol. 2016 Oct;11(10):1606-8. doi: 10.1016/j.jtho.2016.08.125.
3
Are liquid biopsies ready for primetime?液体活检准备好迎接黄金时段了吗？
Cancer. 2019 Mar 15;125(6):834-837. doi: 10.1002/cncr.31644. Epub 2018 Dec 23.
4
Circulating Biomarkers in Glioblastoma: Ready for Prime Time?胶质母细胞瘤中的循环生物标志物：准备好进入黄金时代了吗？
Cancer J. 2021;27(5):404-409. doi: 10.1097/PPO.0000000000000541.
5
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?液体活检在卵巢癌中应用循环肿瘤 DNA 和细胞：是否已经准备好进入黄金时代？
Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11.
6
Preface: Immune Biomarkers from Liquid Biopsies.前言：液体活检中的免疫生物标志物
Crit Rev Immunol. 2022;42(1):v. doi: 10.1615/CritRevImmunol.2022045512.
7
Role of Biomarkers and Biopsy in Hepatocellular Carcinoma.肝癌的生物标志物和活检的作用。
Clin Liver Dis. 2020 Nov;24(4):577-590. doi: 10.1016/j.cld.2020.07.001. Epub 2020 Aug 28.
8
[Breakthrough Technologies: Liquid Biopsy -Chairmen's Introductory Remarks.].[突破性技术：液体活检——主席的介绍性发言。]
Rinsho Byori. 2016 May;64(4):392-393.
9
Role of liquid biopsies in colorectal cancer.液体活检在结直肠癌中的作用。
Curr Probl Cancer. 2018 Nov;42(6):593-600. doi: 10.1016/j.currproblcancer.2018.08.004. Epub 2018 Aug 29.
10
Applications of liquid biopsies for cancer.液体活检在癌症中的应用。
Sci Transl Med. 2019 Aug 28;11(507). doi: 10.1126/scitranslmed.aay1984.
引用本文的文献
1
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.用于 PD-(L)1 轴抑制的生物标志物开发：SITC 生物标志物委员会的共识观点。
J Immunother Cancer. 2024 Jul 20;12(7):e009427. doi: 10.1136/jitc-2024-009427.
2
Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.循环 microRNA-155-3p 水平可预测转移性肾细胞癌患者一线免疫治疗的反应。
Sci Rep. 2024 Apr 13;14(1):8603. doi: 10.1038/s41598-024-59337-4.
3
Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.超越血液：在肿瘤学和个性化医学中推进液体活检的前沿。
Cancer Sci. 2024 Apr;115(4):1060-1072. doi: 10.1111/cas.16097. Epub 2024 Feb 3.
本文引用的文献
1
Regulatory implications of ctDNA in immuno-oncology for solid tumors.ctDNA 在实体瘤免疫肿瘤学中的监管意义。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005344.
2
Evaluation of cell-free DNA approaches for multi-cancer early detection.用于多癌早期检测的游离DNA方法评估。
Cancer Cell. 2022 Dec 12;40(12):1537-1549.e12. doi: 10.1016/j.ccell.2022.10.022. Epub 2022 Nov 17.
3
Access and quality of biomarker testing for precision oncology in Europe.欧洲精准肿瘤学中生物标志物检测的可及性与质量
Eur J Cancer. 2022 Nov;176:70-77. doi: 10.1016/j.ejca.2022.09.005. Epub 2022 Oct 1.
4
Results of a worldwide external quality assessment of cfDNA testing in lung Cancer.全球肺癌 cfDNA 检测外部质量评估结果。
BMC Cancer. 2022 Jul 12;22(1):759. doi: 10.1186/s12885-022-09849-x.
5
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.ESMO 关于使用循环肿瘤 DNA 检测用于癌症患者的建议：来自 ESMO 精准医学工作组的报告。
Ann Oncol. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6.
6
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.循环肿瘤 DNA 分析指导 II 期结肠癌辅助治疗。
N Engl J Med. 2022 Jun 16;386(24):2261-2272. doi: 10.1056/NEJMoa2200075. Epub 2022 Jun 4.
7
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations.基于复发致癌重排的精准联合治疗。
Cancer Discov. 2022 Jun 2;12(6):1542-1559. doi: 10.1158/2159-8290.CD-21-0832.
8
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.ctDNA 动态复发风险和辅助化疗获益预测在可切除 NSCLC 中的应用。
Nat Commun. 2021 Nov 19;12(1):6770. doi: 10.1038/s41467-021-27022-z.
9
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.检测实体瘤的液体残余物：循环肿瘤 DNA 微小残留病。
Cancer Discov. 2021 Dec 1;11(12):2968-2986. doi: 10.1158/2159-8290.CD-21-0634.
10
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.精准肿瘤学时代的癌症生物标志物：满足患者和医疗体系的需求。
Semin Cancer Biol. 2022 Sep;84:293-301. doi: 10.1016/j.semcancer.2021.08.002. Epub 2021 Aug 10.
Zotero 插件